The Evolution of Neoadjuvant Lorlatinib in NSCLC

The landscape of thoracic oncology is shifting rapidly as targeted therapies move from the metastatic setting into earlier stages of disease. Specifically, the use of neoadjuvant Lorlatinib in NSCLC represents a significant breakthrough for patients with ALK-positive tumors who traditionally faced limited surgical options. Historically, clinicians classified stage IIIB non-small cell lung cancer as unresectable due to extensive mediastinal lymph node involvement. However, the advent of third-generation tyrosine kinase inhibitors has changed this paradigm. These potent agents can induce dramatic tumor shrinkage and nodal downstaging, which effectively converts unresectable cases into candidates for radical surgery. Consequently, multidisciplinary teams are now re-evaluating the boundaries of operability. By integrating advanced molecular profiling with precision medicine, surgeons can offer potentially curative interventions to patients who previously relied solely on definitive chemoradiotherapy. This shift emphasizes the importance of a personalized approach in modern lung cancer management, where the focus has moved toward maximizing pathological responses before surgical resection.

Case Presentation: Managing Stage IIIB ALK-Positive NSCLC

A recent case report highlighted a 35-year-old non-smoking female who presented with stage IIIB adenocarcinoma of the left lower lobe. Initial diagnostic imaging revealed a cT1bN2bM0 status, characterized by multiple-station mediastinal lymph node metastasis and a high overall tumor burden. Despite the advanced stage, the patient maintained an excellent performance status with no significant comorbidities. Genetic testing confirmed an ALK-positive status, which immediately suggested a role for targeted therapy. Given the complexity of the nodal involvement, the multidisciplinary team opted for a novel strategy involving neoadjuvant Lorlatinib in NSCLC. The patient received the oral TKI for a duration of 10 weeks, during which clinicians monitored her response closely. Subsequent restaging with PET-CT showed a remarkable complete metabolic response (CMR). Because the tumor exhibited such high sensitivity to the targeted agent, the surgical team determined that a uniportal VATS lobectomy was both feasible and appropriate. This decision-making process illustrates the critical value of restaging imaging in determining the optimal timing for surgical intervention following neoadjuvant treatment.

Clinical Rationale: Why Lorlatinib for Stage III Disease?

Lorlatinib stands out among ALK inhibitors because of its unique pharmacological profile. As a third-generation TKI, it was specifically designed to overcome resistance mutations that often develop after treatment with first-line agents like crizotinib or alectinib. Moreover, Lorlatinib possesses exceptional blood-brain barrier penetration, which is vital given that lung cancer frequently metastasizes to the central nervous system. Although the primary evidence for its efficacy initially came from the metastatic setting, recent trials have explored its use in neoadjuvant protocols. The rationale behind using Neoadjuvant Lorlatinib in NSCLC is to achieve maximum systemic control while reducing the primary tumor volume. Furthermore, this approach addresses micrometastatic disease early in the treatment course, which may reduce the risk of future recurrence. By achieving a high objective response rate, Lorlatinib facilitates R0 resections in patients who would otherwise have faced poor prognoses. Consequently, this case adds to the growing body of evidence supporting the early deployment of highly potent TKIs in locally advanced disease to improve long-term outcomes.

Achieving Pathological Complete Response via Uniportal VATS

The primary goal of neoadjuvant therapy is to reach a pathological complete response (pCR), which serves as a powerful predictor of long-term survival. In this specific case, the transition from a complete metabolic response on PET-CT to a pCR in the surgical specimen was a landmark achievement. After the 10-week course of Lorlatinib, the surgical team performed a uniportal VATS left lower lobectomy combined with systemic lymph node dissection. Pathologists subsequently analyzed the resected tissue and confirmed the total absence of viable tumor cells in both the primary site and the lymph nodes. This finding is significant because it validates the predictive value of CMR in the context of neoadjuvant Lorlatinib in NSCLC. Although a CMR does not always guarantee a pCR, the high correlation observed here suggests that metabolic imaging can guide surgical timing. Furthermore, achieving a pCR in stage IIIB disease is relatively rare, making this case a strong advocate for the neoadjuvant use of third-generation TKIs. Resultantly, the patient remained disease-free at her 12-month follow-up, demonstrating the potential for durable remission through this combined approach.

Surgical Advantages of the Uniportal VATS Approach

The choice of surgical technique plays a crucial role in the recovery and overall experience of the patient. In this instance, the surgeons utilized uniportal VATS, a minimally invasive technique that requires only a single small incision. Compared to traditional multi-portal VATS or open thoracotomy, the uniportal approach offers several distinct advantages. Specifically, it leads to reduced postoperative pain and a lower incidence of intercostal nerve damage. Because the procedure is less traumatic to the chest wall, patients often experience faster recovery of pulmonary function and a shorter hospital stay. For the 35-year-old patient in this report, the hospital stay lasted only five days, and she experienced an uneventful recovery without complications. Additionally, the uniportal approach provides an excellent view of the mediastinal structures, allowing for the meticulous lymph node dissection required in stage III cases. Consequently, the combination of neoadjuvant Lorlatinib in NSCLC and uniportal VATS represents the pinnacle of modern, patient-centric thoracic surgery, balancing oncological radicality with minimal physical impact.

Future Implications for Multidisciplinary Lung Cancer Care

This case report serves as a foundational step toward broader clinical applications of targeted neoadjuvant therapy. While a single-case design has inherent limitations, the results align with emerging data from phase II trials like the LORIN study, which has shown high pCR rates in similar populations. Moving forward, the integration of Neoadjuvant Lorlatinib in NSCLC into standard treatment algorithms will likely depend on larger, randomized controlled trials. These studies must address the optimal duration of neoadjuvant treatment and the necessity of adjuvant therapy following a pCR. Moreover, the role of liquid biopsies in monitoring treatment response could further refine patient selection for surgery. Clinicians must also remain vigilant about the unique side effect profile of Lorlatinib, including hyperlipidemia and cognitive changes, during the preoperative phase. Nevertheless, the success of this case provides a clear roadmap for using potent molecular-targeted therapies to expand the surgical horizon. As precision medicine continues to evolve, the goal of achieving a pCR through minimally invasive means will become increasingly attainable for patients with locally advanced NSCLC.

Frequently Asked Questions

What is the significance of a complete metabolic response (CMR) in neoadjuvant therapy?

A complete metabolic response indicates that the tumor no longer shows significant glucose uptake on a PET-CT scan. In the context of neoadjuvant therapy, a CMR is a highly favorable prognostic sign. It suggests that the treatment has effectively neutralized the metabolic activity of the cancer cells. For patients receiving neoadjuvant Lorlatinib in NSCLC, achieving a CMR often correlates with a high likelihood of finding a pathological complete response during surgery, which is the ultimate goal for long-term survival.

Why is Lorlatinib considered a potent option for ALK-positive NSCLC?

Lorlatinib is a third-generation ALK inhibitor designed to target a wide range of resistance mutations that defeat earlier drugs. It is particularly valued for its superior ability to cross the blood-brain barrier, providing protection against brain metastases. Its high potency allows it to achieve deep responses even in patients with a high tumor burden. Furthermore, its efficacy in the neoadjuvant setting helps in downstaging advanced tumors, making complex surgeries like uniportal VATS safer and more effective for stage III patients.

How does uniportal VATS improve outcomes in stage IIIB NSCLC?

Uniportal VATS improves outcomes by significantly reducing surgical trauma through a single-port access. This technique results in less postoperative pain and fewer complications compared to open surgery. For stage IIIB NSCLC patients who have undergone neoadjuvant therapy, it allows for a precise lobectomy and lymph node dissection while preserving the patient\'s overall strength. Consequently, patients recover faster and can often transition more quickly to any necessary postoperative treatments, leading to a smoother overall clinical journey and improved quality of life.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider regarding a medical condition. The use of specific medications in a neoadjuvant setting may be off-label or subject to local regulatory approvals. Refer to the latest local and national guidelines for clinical practice.

References

Li R et al. From metabolic to pathologic complete response: case report of Neoadjuvant Lorlatinib in Stage IIIB ALK-positive NSCLC combined with uniportal VATS. J Cardiothorac Surg. 2026 Jun 28. doi: 10.1186/s13019-026-04405-1. PMID: 42366402.

Solomon BJ, et al. Lorlatinib in non-small-cell lung cancer. N Engl J Med. 2017;377(22):2101-2114. doi: 10.1056/NEJMoa1711015.

Zhang C, et al. Neoadjuvant lorlatinib in stage III NSCLC harboring ALK fusion: A phase 2 multicenter study (LORIN). J Clin Oncol. 2026;44(suppl; abstr 8012).